In this study, we retrospectively analyzed the efficacy and safety of first-line treatment with 160 mg/d of furmonertinib in patients with advanced NSCLC harboring EGFR ex20ins mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.